skip to main content

Mechanism-Based Hiccup Treatment Selection — SCE Palliative Medicine MCQ

Instant feedback + full explanation. One question, done properly.

HardPain ManagementMechanism-Based Hiccup Treatment SelectionSCE Palliative Medicine

A 55‑year‑old woman with advanced ovarian cancer has severe hiccups for 7 days. Chlorpromazine, baclofen and gabapentin have all failed. A trial of midazolam 2.5 mg subcutaneously PRN temporarily relieves the hiccups. What does this suggest about the mechanism and management?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — The response to a GABA‑A agonist (midazolam) after failure of agents acting via dopamine, GABA‑B, and gabapentinoid mechanisms suggests involvement of a GABA‑A–responsive hiccup reflex pathway; midazolam may be added to the CSCI for continuous suppression

Option D is correct. The sequential failure of chlorpromazine (dopamine antagonist), baclofen (GABA‑B agonist) and gabapentin suggests that the patient's hiccup reflex may not respond to those pathways. The relief with midazolam—a GABA‑A agonist—implies involvement of GABA‑A–mediated inhibition. UK specialist palliative guidelines (Scottish) recommend midazolam 2–5 mg SC PRN or 5–10 mg/24 h via CSCI for persistent hiccups when other treatments have failed. Other options are incorrect: A ignores consistent pharmacological response; B overstates specificity; C ignores appropriate sequence and individualisation; D misattributes mechanism when targeted reflex agents have failed but sedation via GABA‑A succeeds.

Reference: Scottish Palliative Care Guidelines: "Hiccups" and "Midazolam in palliative care" sections, https://www.rightdecisions.scot.nhs.uk/scottish-palliative-care-guidelines/medicines-information/midazolam-in-palliative-care/